Published on
Jul 4, 2025
With FDA Nod in Lung Cancer, Dizal Now Aims to Best a J&J Drug and Succeed Where Takeda Fell Short
One of the more competitive targets in lung cancer is a certain mutation that has eluded many available targeted therapies. A drug developed by Dizal Pharmaceutical has received FDA approval for treating patients whose disease exhibits this genetic …
Source:
MedCity News
-
Neutral
)
